Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)

Arnold W. Cohen, Joshua A. Copel, George A. MacOnes, M. Kathryn Menard, Laura Riley, George R. Saade

Research output: Contribution to journalReview article

16 Scopus citations

Fingerprint Dive into the research topics of 'Unjustified increase in cost of care resulting from U.S. Food and drug administration approval of makena (17α-hydroxyprogesterone caproate)'. Together they form a unique fingerprint.

Medicine & Life Sciences